Project Grant 2507491
Award Date 10/1/25
Completion Date 9/30/26
Dollars Obligated $304K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Newark, DE, USA
Similar Awards
- This STTR Phase I project by Immuno Nano Med, Inc. was awarded a $305,000 grant from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program. The project aims to demonstrate the feasibility of producing a novel room-temperature-stable, dry-powder inhalable influenza vaccine, replacing current needle-based flu shots that require refrigerated storage. This innovative vaccine technology has the potential to significantly lower storage costs, improve...
- This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
- This Small Business Innovation Research (SBIR) Phase I federal grant award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program aims to develop a novel low-cost intradermal vaccine delivery platform for nucleic acid vaccines. The $304,742 award to Piezo Therapeutics, Inc. will demonstrate the feasibility of delivering naked nucleic acid vaccines without lipid nanoparticles using a handheld pen device. The project will optimize...
- The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...
- This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...
- This National Science Foundation (NSF) Small Business Technology Transfer (STTR) Phase I grant, awarded under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program, provides $274,991 to Duravax Inc. to develop thermostable formulations of mRNA vaccines and therapeutics. The project aims to overcome the cold-chain limitations of current mRNA products by demonstrating the feasibility of storing mRNA APIs and mRNA-lipid nanoparticles at room temperature for extended periods. If...
- The National Science Foundation (NSF) awarded a $305,000 Small Business Innovation Research (SBIR) Phase I grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Novaurum Biosciences Incorporated in Somerville, MA. The project aims to develop a novel mammalian cell-based nano-biological coating for implantable medical devices that can inhibit biofilm formation and protect against bacterial infections, including antibiotic-resistant strains, while promoting...
- This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...
- This SBIR Phase II Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program provides $996,606.00 to Invvax, Inc. to develop stable prophylactic antibodies (SPABs) that can serve as long-term preventatives for infectious diseases such as influenza, malaria, tuberculosis, HIV, and the common cold. The project aims to identify antibody mutations that can significantly enhance stability, extending the lifespan of antibodies...
- Altigg Therapeutics, Inc. was awarded a $255,595 Small Business Technology Transfer (STTR) Phase I Project Grant from the National Science Foundation's Engineering program (CFDA 47.041) for the period of April 1, 2021 through March 31, 2022. Under this award, Altigg Therapeutics will develop a platform for the rapid discovery of human antibodies as therapeutics for infectious diseases such as COVID-19. The NSF Engineering program seeks to improve quality of life and economic strength through...